‘I thought if I was slim the world would be some kind of fairy tale': the risks and challenges of weight loss surgery
Jenny Radcliffe in Cut Down to Size, 2013
Vomiting is a common effect of weight loss surgery as you adapt to living with a smaller stomach pouch. Up to two-thirds of patients experience vomiting after surgery, mostly in the months following surgery, but for some continuing for years.21 Ongoing frequent vomiting can be due to medical complications, such as intestinal obstruction, anastomotic stricture, ulcers or blockage of a gastric band, but most commonly is in response to poorly chewed food, inappropriate food choices, mixing drinks with foods or the consumption of overly large portions. To reduce vomiting you need to eat slowly, taking small bites, avoiding tough foods that are difficult to chew to a paste.22 Vomiting can also be caused by dehydration so ensure that you drink plenty of fluids.
Disorders of Consciousness
Philip B. Gorelick, Fernando D. Testai, Graeme J. Hankey, Joanna M. Wardlaw in Hankey's Clinical Neurology, 2020
Clinical assessment includes: Normal rate and depth of respiration, pupillary reactions, muscle tone, deep tendon and abdominal reflexes, and downgoing plantar responses.Forced resistance of eye opening.Slow, roving eye movements and oculocephalic reflex are not present due to suppression from an intact cortex.Optokinetic nystagmus may be present.Irrigation of the ears with ice-cold water is noxious and evokes nystagmus with the fast component beating away from the side of the irrigated ear. Associated nausea with vomiting may occur.
The Epistemology of Medical Error in an Intersectional World
Fritz Allhoff, Sandra L. Borden in Ethics and Error in Medicine, 2019
Tomas experiences standard side effects from his treatments, including severe nausea and vomiting. This includes vomiting every 10–15 minutes, beginning two–three hours following treatment, and continuing uninterrupted for up to an additional 16 hours, after which time the vomiting slows. He is regularly given Compazine and Benadryl—a very low cost, standard treatment at the time in 1991, amounting to just a few dollars per treatment. This anti-emetic treatment, however, appears ineffective in curbing Tomas’s vomiting. With each successive treatment he becomes increasingly weak, and his recovery time longer. Tomas, after two months of treatment, is no longer able to attend school, due in part to the severity of his nausea, vomiting, and related issues: esophageal ulcers, possible pneumonia caused from aspiration, fatigue, and malnourishment. His family has lost significant wages due to Tomas’s care, and his extended time away from school.
The Effects of Perioperative Probiotics on Postoperative Gastrointestinal Function in Patients with Brain Tumors: A Randomized, Placebo-Controlled Study
Published in Nutrition and Cancer, 2023
Mengyang Jiang, Xiaoyu Zhang, Yiqiang Zhang, Yang Liu, Ran Geng, Haixia Liu, Yongxing Sun, Baoguo Wang
Postoperative gastrointestinal function was evaluated by a series of indicators including the time of first stool and flatus after surgery, the number of spontaneous bowel movements a week after surgery, diarrhea, nausea, and vomiting (15,16). Time of solid diet administration was also recorded. The primary outcome was the time of first stool after surgery. The secondary outcomes included assessments of the time of first flatus, spontaneous bowel movements, diarrhea, nausea, and vomiting, changes in gastrointestinal permeability and clinical outcomes. The time of first stool after surgery was defined as the time between the end of operation and the first spontaneous bowel movement. Spontaneous bowel movement was defined as a stool not induced by rescue medication (17). Diarrhea was defined as the condition of having at least three loose, liquid, or watery bowel movements each day (18). Vomiting was defined as episodes of expulsion of gastric content within 24 h, postoperatively (19). Intensity of nausea was measured using the Numeric Rating Scale with values ranging from 0 to 10 (0: no nausea; 10: worst nausea) (20). Gastrointestinal function was evaluated by researchers who were trained by experienced physicians. Data were obtained from daily interviews (between 8 am and 5 pm) with patients and/or their caregivers.
A case series study of hypopituitarism in older patients with and without gastrointestinal symptoms
Published in Postgraduate Medicine, 2018
Xiaowei Li, Hang Yang, Zhijun Duan, Qingyong Chang, Xiaoting Wei, Changjin Li, Ying Ba, Jianling Du
Clinical manifestations of pituitary dysfunction are subtle and nonspecific in most patients, and its etiologies are various: such as pituitary adenomas, congenital cause, traumatic brain injury or cerebrovascular events, extrapituitary cranial irradiation, and infections; therefore, the diagnosis is often delayed. In addition, its etiologies are various such as pituitary adenomas, congenital cause, traumatic brain injury or cerebrovascular events, extrapituitary cranial irradiation, and infections [1,5,8]. This study investigated the characteristics and possible etiologies of patients with gastrointestinal symptoms to improve the chance of early diagnosis. In our study, the patients with hypopituitarism had a variety of gastrointestinal symptoms, including nausea, vomiting, and lack of appetite, which are consistent with other reports [6]. The symptoms occurred independently or coexisted (see Figure 2). The most commonly reported symptoms were nausea and vomiting. In Group G, 18 patients (78.26%) had hyponatremia, with 69.57% and 60.78% of patients reporting hypoadrenalism and hypothyroidism, respectively (see Figure 3).
Practical management of adverse events in patients with advanced systemic mastocytosis receiving midostaurin
Published in Expert Opinion on Biological Therapy, 2021
Jason Gotlib, Hanneke C. Kluin-Nelemans, Cem Akin, Karin Hartmann, Peter Valent, Andreas Reiter
In our experience, nausea may occur daily after taking midostaurin, usually more profoundly after the morning dose and immediately after the initiation of treatment, but symptoms generally improve over time. Vomiting is a less frequent complication in our practice but is second only to nausea in terms of its observed frequency in clinical studies. Respective rates of nausea and vomiting were 79% and 66% in D2201 and 88% and 69% in A2213 (Table 2) [15,16,44]. These findings are consistent with the rates of nausea (83%) and vomiting (61%) observed in the phase 3 trial of midostaurin + chemotherapy for the treatment of FLT3 mutation-positive AML; however, note that instances of grade 3/4 nausea and vomiting were less frequent with midostaurin, which was given at a dosage of 50 mg twice daily rather than the 100 mg twice daily for advSM, than they were in the comparator placebo + chemotherapy arm in that study [39].
Related Knowledge Centers
- Brain Tumor
- Dehydration
- Intracranial Pressure
- Ionizing Radiation
- Mouth
- Gastroenteritis
- Stomach
- Nausea
- Nose
- Foodborne Illness